Psychedelic Therapy Screening Assessment: What It Actually Looks At

Why Executives and High-Performers Are Asking This Question

The conversation around psilocybin-assisted therapy has moved well beyond niche research circles. Executives, physicians, attorneys, and senior operators are increasingly exploring it as a tool for cognitive resilience, burnout recovery, and psychological recalibration. The interest is not casual. It reflects a pattern among high-output individuals who have tried conventional interventions, found them insufficient, and are now asking harder questions about what is actually available to them.

The research is beginning to support that instinct. A 2025 randomized controlled trial published in PLOS Medicine found that psilocybin-assisted group psychotherapy combined with mindfulness-based stress reduction produced clinically significant improvements in depressive symptoms among frontline physicians and nurses, with greater reductions than mindfulness training alone. A separate 2024 randomized clinical trial in JAMA Network Open found significant decreases in depression scores among clinicians following a structured psilocybin protocol involving preparation, dosing, and integration sessions. A large prospective longitudinal survey tracking 2,833 participants before and after a planned psilocybin experience found persisting reductions in anxiety, depression, and burnout at two to three months, along with increased cognitive flexibility and improved emotion regulation. The average participant age was 40, and the majority were college-educated professionals.

These outcomes were produced in carefully screened populations. That detail matters far more than most seekers initially appreciate, and it is the core reason a rigorous intake process exists.

What a Psychedelic Therapy Screening Assessment Actually Does

A rigorous psychedelic therapy screening assessment serves two primary functions. First, it identifies clinical contraindications that could create physical or psychological risk for you specifically. Second, it evaluates your current readiness: whether your life circumstances, psychological stability, and intentions position you for a productive experience rather than a destabilizing one.

This is where “am I a candidate for psilocybin” stops being a rhetorical question and becomes a structured clinical determination. A proper evaluation does not begin and end with a health questionnaire. It involves layered evaluation across multiple domains, each designed to surface information that self-report alone will not catch.

At JourneyŌM, the intake process is concierge-level by design. That means no rushing through forms, no one-size-fits-all eligibility decisions, and no pressure to move forward before you have a clear picture of your own profile. It means a thorough, professionally supported review before any recommendation is made.

The Six Domains a Proper Intake Evaluation Covers

1. Psychiatric History

This is the most consequential domain in any psychedelic therapy intake evaluation. Psilocybin works primarily through agonism at serotonin 2A receptors, producing significant changes in perception, cognition, and emotional processing. For most people, that process is therapeutically useful and manageable. For a subset, it carries meaningful risk that a proper screening is specifically designed to identify.

Clinical trials consistently exclude individuals with a personal or family history of psychosis, schizophrenia, schizoaffective disorder, or bipolar type I disorder. The concern, supported by expert consensus including a 2025 statement from the US National Network of Depression Centers, is that psilocybin may unmask or precipitate mania or psychosis in those with specific psychiatric vulnerabilities. A first-degree relative with bipolar disorder or a psychotic disorder is itself a clinical signal that warrants careful evaluation rather than automatic exclusion, but it requires informed judgment, not a self-assessment.

A systematic review and meta-analysis of 214 studies found that serious adverse events were reported in approximately 4% of participants with preexisting neuropsychiatric conditions, compared to rare events in carefully screened populations. The difference between those outcomes is the quality of screening applied before dosing occurs.

Your assessment will also cover current mood stability, any history of suicidal ideation, trauma load, and whether you have the psychological structure to process an intense internal experience over days and weeks. These are not peripheral considerations. They directly predict outcome.

2. Cardiovascular Status

Psilocybin transiently increases heart rate and blood pressure, an effect comparable in magnitude to moderate physical exertion. For most healthy adults, this is well tolerated and resolves as the session progresses. For individuals with uncontrolled hypertension, coronary artery disease, a history of stroke, heart failure, or serious arrhythmia, this temporary physiological load can carry genuine risk.

A proper intake evaluation reviews your cardiovascular history in detail. Well-managed, stable hypertension is a different clinical picture than uncontrolled cardiovascular disease, and a credible assessment is built to distinguish between them. The goal is not to disqualify anyone prematurely; it is to match the intervention to your actual physiological profile.

3. Current Medications

This domain is among the most technically complex in any psychedelic therapy intake evaluation, and it is the area where self-assessment most consistently falls short. Several medication classes require direct clinical evaluation before psilocybin therapy is appropriate.

Lithium is considered an absolute contraindication. Research analyzing self-reported psychedelic experiences found seizures in 47% of cases where psilocybin or LSD was co-administered with lithium. Oregon’s state-licensed psilocybin program codifies this as a legal exclusion, prohibiting services for anyone who has taken lithium within 30 days. The interaction mechanism is not yet fully understood, which makes clinical disclosure more important, not less.

Monoamine oxidase inhibitors (MAOIs) carry a risk of serotonin toxicity when combined with serotonergic compounds. SSRIs and SNRIs present a more nuanced picture: current evidence suggests they do not significantly increase seizure or serotonin syndrome risk when combined with psilocybin, but they may attenuate therapeutic effect through 5-HT2A receptor downregulation. Whether and how to taper medications before therapy is a decision that requires clinical supervision, not a self-managed protocol. Antipsychotics including olanzapine and risperidone block serotonin 2A receptors and can largely negate psilocybin’s therapeutic effects. A complete medication review, including supplements and over-the-counter compounds, is a non-negotiable component of a credible evaluation.

4. Psychological Readiness and Life Stability

This is the domain that separates a clinical screening from a simple eligibility checklist, and it is where a concierge intake process adds the most value over a standardized form. Psychedelic therapy involves a period of significant internal processing, before, during, and after the session itself. That processing does not occur in a vacuum; it occurs in the context of your current life circumstances.

A proper intake assessment evaluates whether your current situation supports the integration work that produces durable outcomes. Acute life crises, major professional instability, active legal proceedings, or significant relational ruptures can all complicate the post-experience period in ways that limit benefit and increase psychological risk. Raising this during intake is not a judgment of your character or resilience. It is an honest clinical evaluation of whether the timing serves your goals.

The assessment also surfaces your intentions and what you are hoping to address. That clarity, or the absence of it, is itself meaningful clinical information that shapes preparation and the guide relationship.

5. Previous Psychedelic History

Prior experience with psychedelics, both positive and adverse, is relevant data for any psychedelic therapy intake evaluation. A history of difficult or destabilizing experiences warrants clinical attention. Some individuals have had prolonged anxiety, perceptual disturbances, or derealization following previous use, and that history informs both eligibility and preparation approach in a professionally supported context.

Prior positive experience also matters, but it does not function as a green light. What worked in a different context, at a different life stage, with a different support structure, does not automatically replicate under a structured therapeutic protocol. Both types of history belong in the assessment conversation.

6. Support System and Integration Capacity

Clinical protocols consistently identify post-experience integration as a predictor of durable therapeutic outcomes. The work does not end with the session. A proper evaluation considers whether you have adequate personal support in the days and weeks that follow, whether your schedule and obligations allow sufficient recovery time, and whether you are positioned to engage meaningfully with integration rather than moving immediately back to full operational load.

High-performers frequently underestimate the cognitive and emotional bandwidth that meaningful integration requires. Planning for it explicitly, before the experience rather than after, is part of what a concierge process provides.

A Note on Privacy and Confidentiality

This is a question that surfaces consistently among professionals considering psychedelic therapy, and it deserves a direct answer. The intake process at JourneyŌM is confidential. The information you share during your assessment is used to support your process and is not disclosed beyond the concierge team without your consent. For individuals in regulated industries, those with public-facing roles, or anyone who values discretion as a baseline expectation, confidentiality is built into how we operate, not offered as an afterthought.

What Happens When the Assessment Surfaces a Concern

A well-designed psychedelic therapy screening assessment is not a binary gate. It is a tool for understanding your specific clinical picture with enough precision to make a genuinely informed recommendation. If the evaluation surfaces a contraindication, the appropriate professional response is to explain what was found, why it matters in your case, and what options exist going forward. In some situations, that means addressing a medication interaction under medical supervision before proceeding. In others, it means identifying a different intervention better suited to your current profile.

Responsible providers work through complexity with you rather than around it. The assessment exists precisely so that these conversations happen before the experience, not during or after it.

Starting with Assessment Is the Analytical Choice

If you approach this the way you approach any significant decision involving your health or performance, you begin with information. You verify the assumptions. You account for the variables specific to your profile. You build a plan grounded in your actual situation rather than a generalized template that assumes everyone is the same candidate.

A proper psychedelic therapy intake evaluation is exactly that process applied to this decision. It moves you from “I’ve heard this can help” to a grounded, individualized picture of whether it is appropriate for you, what preparation looks like, and what to expect from a professionally supported experience.

The JourneyŌM Free Psychedelic Readiness Assessment is the right place to start. It is structured, confidential, and designed to give you clarity before you commit to anything further.